CA3216939A1 - Procede de titrage de doses d'agents psychedeliques - Google Patents

Procede de titrage de doses d'agents psychedeliques

Info

Publication number
CA3216939A1
CA3216939A1 CA3216939A CA3216939A CA3216939A1 CA 3216939 A1 CA3216939 A1 CA 3216939A1 CA 3216939 A CA3216939 A CA 3216939A CA 3216939 A CA3216939 A CA 3216939A CA 3216939 A1 CA3216939 A1 CA 3216939A1
Authority
CA
Canada
Prior art keywords
dose
administering
psychedelic
individual
time
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3216939A
Other languages
English (en)
Inventor
Robert Barrow
Daniel R. Karlin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mind Medicine Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA3216939A1 publication Critical patent/CA3216939A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Dental Preparations (AREA)
  • Measurement Of Radiation (AREA)

Abstract

Un procédé de dosage d'un agent psychédélique qui évite les effets secondaires des hallucinations et des perturbations perceptives par administration de l'agent psychédélique à un sujet dans le cadre d'un régime posologique par titrage et par réduction des effets secondaires des hallucinations et des perturbations perceptives. Un kit d'administration d'un régime posologique par titrage d'un agent psychédélique comprend une quantité pharmaceutiquement efficace de l'agent psychédélique dans des formes posologiques séparées dans l'emballage selon la dose et l'heure d'administration dans le cadre d'un régime posologique par titrage et des instructions d'utilisation. Un procédé de traitement d'un sujet par agents psychédéliques, par administration de l'agent psychédélique au sujet ayant un état ou une maladie dans le cadre d'un régime posologique par titrage et par réduction des effets secondaires des hallucinations et des perturbations perceptives pendant le traitement.
CA3216939A 2021-05-03 2022-05-01 Procede de titrage de doses d'agents psychedeliques Pending CA3216939A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163183579P 2021-05-03 2021-05-03
US63/183,579 2021-05-03
PCT/US2022/027179 WO2022235529A1 (fr) 2021-05-03 2022-05-01 Procédé de titrage de doses d'agents psychédéliques

Publications (1)

Publication Number Publication Date
CA3216939A1 true CA3216939A1 (fr) 2022-11-10

Family

ID=83932279

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3216939A Pending CA3216939A1 (fr) 2021-05-03 2022-05-01 Procede de titrage de doses d'agents psychedeliques

Country Status (7)

Country Link
EP (1) EP4333979A1 (fr)
JP (1) JP2024517194A (fr)
AU (1) AU2022268891A1 (fr)
CA (1) CA3216939A1 (fr)
IL (1) IL308068A (fr)
TW (1) TW202245767A (fr)
WO (1) WO2022235529A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022287974A1 (en) 2021-06-09 2024-01-04 Atai Therapeutics, Inc. Novel prodrugs and conjugates of dimethyltryptamine
EP4387612A1 (fr) 2021-08-20 2024-06-26 Pharmala Biotech Inc. Compositions comprenant des mélanges non racémiques de (r)-et (s)-3,4-méthylènedioxyméthamphétamine ou (r) et (s) n-méthyl -1,3-benzodioxolylbutanamine et leurs utilisations
US12012381B2 (en) 2021-12-30 2024-06-18 Atai Therapeutics, Inc. Dimethyltryptamine analogues as nitric oxide delivery drugs
WO2023168023A1 (fr) 2022-03-04 2023-09-07 Reset Pharmaceuticals, Inc. Co-cristaux ou sels comprenant de la psilocine

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019081764A1 (fr) * 2017-10-26 2019-05-02 Consejo Superior De Investigaciones Científicas (Csic) Produit d'association pour le traitement de troubles neurologiques et/ou psychiatriques
CA3146050A1 (fr) * 2019-07-04 2021-01-07 Sw Holdings, Inc. Compositions de dosage et procedes d'utilisation de composes psychedeliques

Also Published As

Publication number Publication date
JP2024517194A (ja) 2024-04-19
TW202245767A (zh) 2022-12-01
WO2022235529A1 (fr) 2022-11-10
AU2022268891A1 (en) 2023-11-09
IL308068A (en) 2023-12-01
EP4333979A1 (fr) 2024-03-13

Similar Documents

Publication Publication Date Title
CA3216939A1 (fr) Procede de titrage de doses d'agents psychedeliques
US20080089861A1 (en) Combination therapy for treatment of demyelinating conditions
AU2021227523B2 (en) Controlling effects after 5HT2A agonists administration
US20180235906A1 (en) Anxiolytic composition, formulation and method of use
MX2014010939A (es) Esketamina para el tratamiento de la depresion refractaria al tratamiento o resistente al tratamiento.
JP2007522248A (ja) てんかんおよび他のｃｎｓ障害の処置のための、ｎｍｄａレセプターアンタゴニストと抗てんかん薬との組み合わせ
MX2007015838A (es) Dronabinol para el tratamiento de migranas.
RU2268725C2 (ru) Комбинация лекарственных препаратов, включающая миртазапин, для лечения депрессии и связанных расстройств
WO2022265878A1 (fr) Lutte contre des effets suite à l'administration d'agonistes de 5ht2a
WO2022235500A1 (fr) Psychémie pour le traitement de la douleur
US20230346645A1 (en) Method of titrating dose of psychedelics
WO2014148951A1 (fr) Nouvelle combinaisons thérapeutiques de mirtazapine destinées à s'utiliser en cas de troubles douloureux
Matsuki et al. Survey on choice of intravenous sedative agent at department of dental anesthesiology, Tokyo Dental College Chiba Hospital between 2010 and 2011
EP3612229A1 (fr) Mélange de kétamine et de propofol
CN105935443A (zh) 一种治疗糖尿病性白内障的药物组合物
CN1751691A (zh) 天麻素静脉小容量注射剂及其制备方法
MX2015003879A (es) Metodos para aliviar sintomas de esclerosis multiple basados en composiciones que contienen apoaecuorina.
WO2013098049A1 (fr) Prévention ou traitement de polyneuropathies douloureuses par administration d'aluminosilicate
US8680145B1 (en) Compositions and methods for treatment of fear of medical procedures
US20240226056A1 (en) Sleep or Post-Sleep Performance
WO2023060024A1 (fr) Ganaxolone pour le traitement de la sclérose tubéreuse de bourneville et de troubles épileptiques

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20231026

EEER Examination request

Effective date: 20231026

EEER Examination request

Effective date: 20231026